<DOC>
	<DOCNO>NCT00677872</DOCNO>
	<brief_summary>A 3-month open label study evaluate safety efficacy PRX-08066 patient pulmonary hypertension COPD .</brief_summary>
	<brief_title>An Open-Label Study Evaluate Safety Efficacy PRX-08066 Patients With Pulmonary Hypertension Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Men Women &gt; 40 year age Diagnosis COPD FEV1 20 % le 65 % predict normal FEV1toFVC ratio le 70 % Diagnosis pulmonary hypertension base echocardiography within last 6 month cardiac catheterization within last 12 month New York Heart Association ( NYHA ) Class II III Screening LVEF &gt; 55 % , obtain appropriate method within 6 month screen Baseline 6MWT distance &gt; 150m &lt; 450m Written inform consent subject prior initiation studyrelated procedure Documented negative result ( within 12 month ) Hepatitis B Hepatitis C Serology Treatment pulmonary hypertension epoprostenol ( prostacyclin ) , trepostinil ( Remodulin ) , iloprost ( Ventavis ) , bosentan ( Tracleer ) , ambrisentan ( Letairis ) , sildenafil ( Viagra ) , tadalafil ( Cialis ) , vardenafil ( Levitra ) within 30 day prior study entry Presence history follow cardiovascular comorbidities condition : Uncontrolled systemic hypertension screening ; unstable cardiovascular disease include intermittent atrial fibrillation unstable angina within 4 week prior screen ; amyloidosis , hypertrophic obstructive cardiomyopathy , restrictive cardiomyopathy , constrictive pericarditis ; history myocardial infarction , coronary artery bypass graft surgery , percutaneous cardiac intervention within 3 month prior screen ; significant valvular heart disease ; cerebrovascular accident transient ischemic attack within 3 month prior screen COPD exacerbation le 1 month prior screen Exercise tolerance limit noncardiac cause Clinically significant psychiatric , addictive , neurologic disease condition Chronic renal impairment renal insufficiency No clinically significant laboratory abnormality Subjects currently treat PH prostnoids , PDE5 inhibitor endothelin receptor antagonist . The use PDE5 inhibitor `` need '' erectile dysfunction acceptable long subject take medication within 72 hour efficacy assessment . Other concomitant medication allow provide subject stable dose regimen least 4 week prior enrollment regimen continue remain stable treatment followup period . History nasal airway mass , septal perforation , chronic sinusitis , lidocaine allergy current nasal passage condition would decrease safety tolerability nasoesophageal catheter The subject presence , history , malignancy require significant medical intervention within precede 3 month and/or likely result death within next 2 year The receipt investigational medication within 30 day prior screen anytime course study Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Moderate severe COPD coincident pulmonary hypertension</keyword>
</DOC>